An observational study in Bicuspid Aortic Valve, sponsored by Cedars-Sinai Medical Center. Recruiting at 1 site in United States. Open to participants aged 19 Years to 129 Years. Per ClinicalTrials.gov, last updated 2019-02-11.
Sponsored by Cedars-Sinai Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Bicuspid Aortic Valve Disease with a site in United States — 6 open to participants now, 10 under way, none of them phase 3. Bicuspid Aortic Valve Disease · United States.
Among the 19 studies in Bicuspid Aortic Valve Disease with a site in United States, this one is the 7th largest by planned enrollment of the 12 observational ones that give a count, is one of 3 that started in 2016, is one of 12 observational ones, and was the 16th registered.
62 studies on the registry are indexed under Bicuspid Aortic Valve Disease; 21 are open to participants now.
Browse Bicuspid Aortic Valve Disease studies →6 of the 19 studies in Bicuspid Aortic Valve Disease with a site in United States are open now. Recruiting first, the newest first:
Cedars-Sinai Medical Center · Sites in United States
Ages 50+
Cedars-Sinai Medical Center · Sites in United States
Ages 50+
University of Pennsylvania · Sites in United States
Ages 18+
University of Michigan · Sites in United States
Healthy volunteers
University of Michigan · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 17 Bicuspid Aortic Valve Disease studies recruiting now, 12 (71%) set no upper age limit and 3 (18%) stop at 75 or younger; 5 take children under 18; 2 take healthy volunteers.
This study: 19 Years to 129 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 236 across 38 observational studies indexed under Bicuspid Aortic Valve Disease.
Median enrollment 60 across the 7 interventional studies, 2,500 across the 12 observational. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 19 have an industry lead sponsor. The 10 most frequent:
Cedars-Sinai Medical Center is the lead sponsor of 457 studies on the registry; 108 are open to participants now.
Of its 65 completed or terminated interventional studies of FDA-regulated products, 49 (75%) have results posted.
Cedars-Sinai Medical Center has 3 studies filed under Bicuspid Aortic Valve Disease — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Bicuspid Aortic Valve Disease with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the procedural and clinical outcomes of patients with bicuspid aortic valve stenosis undergoing transcatheter aortic valve replacement.
All consecutive patients presenting with severe and symptomatic bicuspid aortic valve stenosis or mixed disease
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Death
Death from any cause
Time frame: 1 month
Death
Death from any cause
Time frame: 1 year
Death
Death from any cause
Time frame: 2 years
Death
Death from any cause
Time frame: 3 years
Death
Death from any cause
Time frame: 4 years
Death
Death from any cause
Time frame: 5 years
Death from cardiac cause
Death from cardiac cause
Time frame: 1 month
Death from cardiac cause
Death from cardiac cause
Time frame: 1 year
Death from cardiac cause
Death from cardiac cause
Time frame: 2 years
Death from cardiac cause
Death from cardiac cause
Time frame: 3 years
Death from cardiac cause
Death from cardiac cause
Time frame: 4 years
Death from cardiac cause
Death from cardiac cause
Time frame: 5 years
Stroke
disabling and non-disabling stroke
Time frame: 1 month
Stroke
disabling and non-disabling stroke
Time frame: 1 year
Stroke
disabling and non-disabling stroke
Time frame: 2 years
Stroke
disabling and non-disabling stroke
Time frame: 3 years
Stroke
disabling and non-disabling stroke
Time frame: 4 years
Stroke
disabling and non-disabling stroke
Time frame: 5 years
Repeat hospitalization
Number of hospitalizations
Time frame: 1 month
Repeat hospitalization
Number of hospitalizations
Time frame: 1 year
Repeat hospitalization
Number of hospitalizations
Time frame: 2 years
Repeat hospitalization
Number of hospitalizations
Time frame: 3 years
Repeat hospitalization
Number of hospitalizations
Time frame: 4 years
Repeat hospitalization
Number of hospitalizations
Time frame: 5 years
Bleeding
Life-threatening or major bleeding rate
Time frame: 1 month
Bleeding
Life-threatening or major bleeding rate
Time frame: 1 year
Bleeding
Life-threatening or major bleeding rate
Time frame: 2 years
Bleeding
Life-threatening or major bleeding rate
Time frame: 3 years
Bleeding
Life-threatening or major bleeding rate
Time frame: 4 years
Bleeding
Life-threatening or major bleeding rate
Time frame: 5 years
Vascular complication
Major vascular complication
Time frame: 1 month
Vascular complication
Major vascular complication
Time frame: 1 year
Vascular complication
Major vascular complication
Time frame: 2 years
Vascular complication
Major vascular complication
Time frame: 3 years
Vascular complication
Major vascular complication
Time frame: 4 years
Vascular complication
Major vascular complication
Time frame: 5 years
Acute kidney injury (stage 2 or 3)
Time frame: 1 month
Acute kidney injury (stage 2 or 3)
Time frame: 1 year
Acute kidney injury (stage 2 or 3)
Time frame: 2 years
Acute kidney injury (stage 2 or 3)
Time frame: 3 years
Acute kidney injury (stage 2 or 3)
Time frame: 4 years
Acute kidney injury (stage 2 or 3)
Time frame: 5 years
Prosthetic regurgitation by Doppler echocardiography
Time frame: at discharge
Prosthetic regurgitation by Doppler echocardiography
Time frame: 1 month
Prosthetic regurgitation by Doppler echocardiography
Time frame: 1 year
Prosthetic regurgitation by Doppler echocardiography
Time frame: 2 years
Prosthetic regurgitation by Doppler echocardiography
Time frame: 3 years
Prosthetic regurgitation by Doppler echocardiography
Time frame: 4 years
Prosthetic regurgitation by Doppler echocardiography
Time frame: 5 years
Mean aortic valve gradient by Doppler echocardiography
Time frame: 1 month
Mean aortic valve gradient by Doppler echocardiography
Time frame: 1 year
Mean aortic valve gradient by Doppler echocardiography
Time frame: 2 years
Mean aortic valve gradient by Doppler echocardiography
Time frame: 3 years
Mean aortic valve gradient by Doppler echocardiography
Time frame: 4 years
Mean aortic valve gradient by Doppler echocardiography
Time frame: 5 years
Started Aug 2016 (actual). Primary completion is estimated for Aug 2028, 144 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bicuspid Aortic Valve Disease →